Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SERA
Upturn stock ratingUpturn stock rating

Sera Prognostics Inc (SERA)

Upturn stock ratingUpturn stock rating
$2.25
Last Close (24-hour delay)
Profit since last BUY-22.41%
upturn advisory
SELL
SELL since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: SERA (1-star) is a SELL. SELL since 1 days. Profits (-22.41%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $2.75

1 Year Target Price $2.75

Analysts Price Target For last 52 week
$2.75 Target price
52w Low $1.37
Current$2.25
52w High $9.13

Analysis of Past Performance

Type Stock
Historic Profit 44%
Avg. Invested days 23
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 85.64M USD
Price to earnings Ratio -
1Y Target Price 2.75
Price to earnings Ratio -
1Y Target Price 2.75
Volume (30-day avg) 2
Beta 0.99
52 Weeks Range 1.37 - 9.13
Updated Date 08/15/2025
52 Weeks Range 1.37 - 9.13
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.85

Earnings Date

Report Date 2025-08-06
When -
Estimate -0.23
Actual -0.16

Profitability

Profit Margin -
Operating Margin (TTM) -54823.53%

Management Effectiveness

Return on Assets (TTM) -23.42%
Return on Equity (TTM) -44.24%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 45830202
Price to Sales(TTM) 792.96
Enterprise Value 45830202
Price to Sales(TTM) 792.96
Enterprise Value to Revenue 424.35
Enterprise Value to EBITDA -0.61
Shares Outstanding 37094100
Shares Floating 24996751
Shares Outstanding 37094100
Shares Floating 24996751
Percent Insiders 10.87
Percent Institutions 64.58

ai summary icon Upturn AI SWOT

Sera Prognostics Inc

stock logo

Company Overview

overview logo History and Background

Sera Prognostics Inc. was founded in 2010 and is focused on improving maternal and fetal health through innovative diagnostic testing. The company went public in 2021.

business area logo Core Business Areas

  • PreTRM Test: A blood test predicting the risk of spontaneous preterm birth. Its intended to help clinicians make informed decisions about patient care.

leadership logo Leadership and Structure

Gregory C. Critchfield, M.D., M.S. is the Chairman, President, and CEO. The company has a board of directors and operates with a functional organizational structure.

Top Products and Market Share

overview logo Key Offerings

  • PreTRM Test: A blood test that predicts a woman's risk of spontaneous preterm birth. Revenue data specific to the PreTRM test is not publicly broken out. Competitors include traditional methods of assessing preterm birth risk, such as assessing risk factors during prenatal visits and ultrasound to measure cervical length.

Market Dynamics

industry overview logo Industry Overview

The industry focuses on maternal and fetal health diagnostics, addressing unmet needs in predicting and preventing pregnancy complications. There's a growing demand for advanced diagnostic solutions.

Positioning

Sera Prognostics aims to be a leader in predicting preterm birth risk with its PreTRM test. Their competitive advantage lies in its predictive accuracy. They are also pursuing market development efforts, including partnerships to integrate their test into standard clinical practice.

Total Addressable Market (TAM)

The estimated TAM for preterm birth prediction is several billion dollars globally. Sera Prognostics is positioning itself to capture a significant share through increased adoption of its PreTRM test.

Upturn SWOT Analysis

Strengths

  • Proprietary technology in preterm birth prediction
  • Published clinical validation data
  • Focus on an unmet medical need

Weaknesses

  • Limited commercial adoption
  • Reliance on a single product (PreTRM)
  • High cash burn

Opportunities

  • Expanding insurance coverage and reimbursement
  • Partnering with large healthcare systems
  • Developing additional maternal health diagnostics

Threats

  • Competition from alternative diagnostic methods
  • Regulatory hurdles
  • Slow adoption by clinicians and patients

Competitors and Market Share

competitor logo Key Competitors

  • NXGN
  • MTBC

Competitive Landscape

Sera Prognostics competes with traditional assessment methods and other diagnostic companies. Its advantage lies in the published data supporting the PreTRM test's predictive ability. Disadvantages include limited commercial traction and competition.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by increased sales of the PreTRM test.

Future Projections: Future growth is dependent on increased adoption of the PreTRM test, expanding insurance coverage, and potential new product development. Analyst estimates should be consulted for specific projections.

Recent Initiatives: Recent initiatives include partnerships with healthcare providers and efforts to expand insurance coverage.

Summary

Sera Prognostics has the potential to become a key player in the field of predictive maternal health diagnostics. The PreTRM test addresses a critical unmet need, but the company faces challenges related to commercial adoption, competition, and financial stability. Successful execution of its growth strategy is vital for long-term success and it needs to look out for increased cash burn.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings, press releases, analyst reports

Disclaimers:

This analysis is based on publicly available information and should not be considered financial advice. Investing in Sera Prognostics involves risks, including the potential loss of capital.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Sera Prognostics Inc

Exchange NASDAQ
Headquaters Salt Lake City, UT, United States
IPO Launch date 2021-07-15
President, CEO & Director Ms. Evguenia Lindgardt M.B.A.
Sector Healthcare
Industry Medical Devices
Full time employees 63
Full time employees 63

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.